bio chat
On the clinical
diagnostics
side, while we
get benchmarked
against the
world’s best,
we also believe
in the “Make in
India” mandate,
in particular,
providing our
products at
affordable cost is
a serious part of
our vision
every individual who
wants to get screened,
tested and regularly
monitored should have
access to these tests.
As an organization, we
believe this will minimize
the disease burden on
our economy and the
financial burden on
individuals. We also
look at driving a larger
alignment within doctor
and patients towards
precision medication
and how relevant
genetic diagnostics can
support that.
Align with government
on helping form policies
38
BioVoiceNews | May 2017
that would drive
alignment towards need
for precision treatment in
the areas of Oncology and
Rare Diseases.
Why don’t we see
more indigenous
startups or companies
venturing into NGS?
A space like NGS requires
a high level of versatile
intellect from the
perspective of bioscience
and bioinformatics.
This obviously means
aggregating the best of
minds in both areas to
collaboratively work
together. For Strand Life
Sciences, it has been a
decade plus journey to
get the levels of product
depth, quality and market
share it has today.
Genomic analysis also
falls under the ambit
of big data. This space
requires continuous
innovation and
investment that most
commercially inclined
organizations may not
have the passion, patience
and perseverance for.
Strand Life Science as an
organization has always
tried to ensure a fair
balance of academic spirit,
with its Indian Institute
of Science lineage, and
market approach.
How do you compare
the past & future
of Indian biotech
industry? What are
the challenges &
opportunities?
A few companies
focused on different
aspects of biotechnology
emerged. These were on
the bioinformatics or